

## Descovy<sup>®</sup> (FTC/TAF)

# Coadministration with Metformin

This document is in response to your request for information regarding Descovy<sup>®</sup> (emtricitabine/tenofovir alafenamide [FTC/TAF]) and coadministration with metformin.

Some data may be outside of the US FDA-approved Prescribing Information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA approved prescribing information.

**The full indication, important safety information, and boxed warnings are available at: [www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy\\_pi](http://www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy_pi).**

## PK DDI Evaluation

This interaction has not been studied between the fixed-dose combination FTC/TAF and metformin. Based on the PK profile of each active ingredient within FTC/TAF and metformin, a PK interaction would not be predicted.<sup>1,2</sup> For more information about metformin, please refer to its product labeling.<sup>2</sup>

### FTC/TAF PK<sup>1</sup>

DDI Mechanism		FTC	TAF
Drug Transporters	P-gp/BCRP	N/A	Substrate
	OATP1B1	N/A	Substrate
	OATP1B3	N/A	Substrate
Drug Metabolizing Enzymes	CYP3A	N/A	Minor Substrate

## Relevant FTC/TAF Label Information

There is no information in the FTC/TAF product labeling about the coadministration of FTC/TAF and metformin.<sup>1</sup>

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including FTC, a component of FTC/TAF, and TDF, another prodrug of tenofovir, alone or in combination with other antiretrovirals. Treatment with FTC/TAF should be suspended in any individual who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).<sup>1</sup>

For information regarding metformin and lactic acidosis, please refer to its product labeling.<sup>2</sup>

## Available Data

There are no Gilead studies evaluating the coadministration of FTC/TAF and metformin.

Additionally, a literature search was conducted in Ovid MEDLINE and Embase databases for studies published between 1946 and April 28, 2025 using search terms that included Descovy, emtricitabine, tenofovir alafenamide, metformin, and related search terms. No relevant citations were found.

---

## References

1. Enclosed. Gilead Sciences Inc, DESCOVY® (emtricitabine and tenofovir alafenamide) tablets, for oral use. U.S. Prescribing Information. Foster City, CA.
  2. Bristol-Myers Squibb Company. GLUCOPHAGE® (metformin hydrochloride) tablets, for oral use. GLUCOPHAGE® XR (metformin hydrochloride) extended-release tablets, for oral use U.S. Prescribing Information. Princeton, NJ.
- 

## Abbreviations

BCRP=breast cancer  
resistance protein  
DDI=drug-drug interaction

FTC=emtricitabine  
OATP=organic anion  
transporting polypeptide  
P-gp=P-glycoprotein

PK=pharmacokinetic(s)  
TAF=tenofovir alafenamide  
TDF=tenofovir disoproxil  
fumarate

---

## Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Descovy US Prescribing Information available at:

[www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy\\_pi](http://www.gilead.com/-/media/files/pdfs/medicines/hiv/descovy/descovy_pi).

## Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎ 1-866-MEDI-GSI (1-866-633-4474) or 🌐 [www.askgileadmedical.com](http://www.askgileadmedical.com)

## Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or

🌐 [www.gilead.com/utility/contact/report-an-adverse-event](http://www.gilead.com/utility/contact/report-an-adverse-event)

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉ MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🌐 [www.accessdata.fda.gov/scripts/medwatch](http://www.accessdata.fda.gov/scripts/medwatch)

## Data Privacy

The Medical Information service at Gilead Sciences may collect, store and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement ([www.gilead.com/privacy-statements](http://www.gilead.com/privacy-statements)) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact [privacy@gilead.com](mailto:privacy@gilead.com).

DESCOVY, GILEAD, and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

© 2025 Gilead Sciences, Inc.